Clinical Presentation and Management of Autoimmune Encephalitis

Prof Osheik Abu'Asha Seidi

MRCP(UK), ABIM, CCST (UK), FRCPG, FRCPE ,FRCP,FAAN

Dean, Deanship of Scientific Research
University of Khartoum, Sudan

Senior Consultant Neurologist
University of Khartoum, Sudan
HMG Riyadh , Saudi Arabia

Seoul. South Korea
19th October 2025

WORLD FEDERATION OF NEUROLOGY
XXVII WORLD CONGRESS OF NEUROLOGY (WCN 2025)
12-15 OCTOBER 2025 | SEOUL, SOUTH KOREA
KNA KOREAN NEUROLOGICAL ASSOCIATION

WORLD FEDERATION OF NEUROLOGY

XXVII WORLD CONGRESS OF NEUROLOGY (WCN 2025)

12-15 OCTOBER 2025 | SEOUL, SOUTH KOREA

KOREAN NEUROLOGICAL ASSOCIATION

Disclosure

I have nothing to disclose in relation to this presentation

DSR Deanship Scientific Research عمادة البحث العلمي

DR SULAIMAN AL HABIB medical group

Objectives

1-Recognize the clinical clues for early detection of Autoimmune Encephalitis (AIE)

2-Highlight the spectrum of the clinical features of the various types of the AIE syndromes, particularly the very characteristic ones . An example is Facio-brachial dystonic seizures with anti LGI1 associated AIE

3-Select and interpret the specific tests for confirmation of the distinct antibodies related AIE syndromes -for surface and intracellular neuronal antigens examples are anti:LGI1,NMDA, GABA a, GABA b, GAD, CASPR2, DPPX,AMPA and IgLON5.

4-Recognise the potentially treatable associated disorders principally tumours. Examples are: ovarian teratomas with anti NMDA, thymoma with anti LGI1, and small cel lung cancer with GABA and AMPA

5-Discuss the treatment modalities for the various types of AIE including immuno-modulation, immuno-supersession, treatment of complications and underlying disorders

Key Message:

Workshop on:
Autoimmune Neurology associated with neuronal antibodies

Autoimmune neurology is a rapidly expanding spectrum of disorders which are potentially treatable if recognised and managed early and effectively.
This course will address these important points

References:

1: Autoimmune encephalitis: clinical spectrum and management Christopher E Uy, Sophie Binks, Sarosh R Irani

Pract Neuro1. 2021 Oct; 21(5): 412-423. Published online 2021 Jun 9. doi:10.1136/practneurol-2020-002567 PMCID:PMC8461404

2.Aladashvili Z, Lupia B, Rodriguez TB, Pontes AB, Buryk Y. A Multidisciplinary Approach to a Treatment-Resistant Anti-N-Methyl-D-Aspartate Receptor Encephalitis Patient in the ICU: A Case Report. Cureus. 2025;17(6):e85605.

3.Arzalluz-Luque J, Dumez P, Picard G, Benaiteau M, Bonjour M, Lardeux P, et al. Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy. J Neurol. 2025;272(6):421.

4. Varley JA, et al. Autoimmune encephalitis: recent clinical and biological advances. J Neurol. 2023;270(8):4118-4131. doi:10.1007/s00415-023-11685-3

5. Daau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840-851. doi:10.1056/NEJMra1708712

6. Thompson J, et al. Early immunotherapy's importance in faciobrachial dystonic seizures. Brain. 2018;141(2):348-356. doi:10.1093/brain/awx323

7. Irani SR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892-900. doi:10.1002/ana.22307

8. Irani SR, et al. Immunotherapy and cognitive outcomes in faciobrachial dystonic seizures. Brain. 2013;136(pt 10):3151-3162. doi:10.1093/brain/awt212

9. Kalra A, Mackay O, Thomas-Jones E, Solomon T, Foscarini-Craggs P. Does the Use of Intravenous Immunoglobulin Improve Clinical Outcomes in Adults With Autoimmune Encephalitis? A Systematic Review. Brain Behav. 2025;15(5):e70491.

10.Wu J, Li X, Peng J, Fu W, Chen S, Wu H. Treatment update for autoimmune/immune-mediated central nervous system diseases. Folia Neuropathol. 2025;63(1):19-29.